Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
REGN | NASDAQ | USD | Real-time | |
1REGN | Milan | EUR | Real-time | |
REGN | Frankfurt | EUR | Delayed | |
REGN | TradeGate | EUR | Delayed | |
REGN34 | B3 | BRL | Delayed | |
REGN | Vienna | EUR | Real-time | |
REGN | Lima | USD | Delayed |
Regeneron Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported revenue was USD 3,720.7 million compared to USD 3,362.7 million a year ago. Net income was USD 1,340.6 million compared to USD 1,007.8 million a year ago. Basic earnings per share from continuing operations was USD 12.4 compared to USD 9.48 a year ago. Diluted earnings per share from continuing operations was USD 11.54 compared to USD 8.89 a year ago. For the nine months, revenue was USD 10,412.8 million compared to USD 9,682.9 million a year ago. Net income was USD 3,494.9 million compared to USD 2,794 million a year ago. Basic earnings per share from continuing operations was USD 32.36 compared to USD 26.16 a year ago. Diluted earnings per share from continuing operations was USD 30.23 compared to USD 24.57 a year ago.
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Total Revenue | 3720.7 | 3547.1 | 3145 | 3434.3 |
Gross Profit | 1958.1 | 2944.5 | 1462.8 | 1740.1 |
Operating Income | 1243.7 | 1093.5 | 758.5 | 1002.9 |
Net Income | 1340.6 | 1432.3 | 722 | 1159.6 |
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Total Assets | 37441.9 | 36086.8 | 34369.6 | 33080.2 |
Total Liabilities | 8116 | 7881 | 7378.5 | 7107.1 |
Total Equity | 29325.9 | 28205.8 | 26991.1 | 25973.1 |
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 1291.2 | 354 | 1512.5 | 1089.7 |
Cash From Investing Activities | -574.4 | -557.2 | -1687.1 | -66.2 |
Cash From Financing Activities | -634 | -478.1 | 47.1 | -446.1 |
Net Change in Cash | 83.6 | -681.6 | -128 | 577.6 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review